As Zhou et al. already found that SRSF1 is immunohistochemically expressed with an increasing gradient in WHO grade II to IV astrocytic neoplasms, we preferred to include in our series gliomas in which the expression of SRSF1 had not yet been tested, such as oligodendrogliomas, ependymomas, PAs, SEGAs and PXAs. This evidence concerns the gene SRSF1 and ependymoma.